Related Experiment Video
Updated: Oct 21, 2025
Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
Published on: March 25, 2016
Vaccination of Pregnant Women Against COVID-19
1Department of Pediatrics and British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Insights
Pregnant women
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Vaccinology
Background:
- Pregnant women face higher risks from SARS-CoV-2 infection.
- Early COVID-19 vaccine recommendations for pregnant individuals were based on pre-pandemic immunity data.
- Increasing pre-existing immunity in pregnant populations may alter infection susceptibility and vaccine responses.
Purpose of the Study:
- To analyze how pre-existing immunity influences SARS-CoV-2 infection severity and vaccine effectiveness in pregnant women.
- To provide context for interpreting maternal COVID-19 vaccine trial data.
Main Methods:
- Review of existing literature on SARS-CoV-2 infection in pregnancy.
- Analysis of epidemiological data regarding pre-existing immunity trends.
- Evaluation of vaccine trial methodologies and outcomes in pregnant populations.
Main Results:
- Pre-existing immunity from prior infection or vaccination may reduce severe outcomes from SARS-CoV-2 in pregnant women.
- The impact of pre-existing immunity on vaccine reactogenicity, immunogenicity, and efficacy in pregnancy requires further investigation.
- Timing of maternal vaccine trials relative to pandemic progression and immunity levels is crucial for accurate interpretation.
Conclusions:
- Future assessments of COVID-19 vaccines in pregnant women must account for varying levels of pre-existing immunity.
- Understanding the evolving landscape of immunity is vital for public health strategies concerning pregnant populations and infectious diseases.
- Further research is needed to fully elucidate the interplay between pre-existing immunity, SARS-CoV-2 infection, and vaccination in pregnancy.
Abstract:
Pregnant women are at increased risk for severe morbidity and mortality following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading some countries to recommend vaccination of pregnant women against coronavirus disease 2019 (COVID-19). These recommendations are based on studies conducted early in the pandemic, and thus, the pregnant women in these studies most likely did not have pre-existing immunity to SARS-CoV-2 at the time of infection. The susceptibility of pregnant women and their infants to SARS-CoV-2 and the severity of infection may be attenuated as the pandemic progresses and an increasing number of women will have pre-existing immunity (following natural infection or vaccination prior to pregnancy) during pregnancy. The reactogenicity, immunogenicity and efficacy of COVID-19 vaccines administered in pregnancy may also be affected by the pre-existing immunity of pregnant women. Maternal vaccine trials should be evaluated in the context of their timing in the pandemic and interpreted based on the pre-existing immunity of pregnant women.
More Related Videos
13:00Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
Published on: July 31, 2021
10:16Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
Published on: August 17, 2022
Related Concept Videos
01:51Vaccinations
01:07Teratogenicity
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:19Mitral Valve Prolapse III: Nursing Management
01:15Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...